Comments on the new guidelines will be accepted until Sept. 18. “The Biden administration has been very vocal in saying they’re going to be very aggressive in the number of challenges and in trying novel theories of potential harm,” said Lauren Norris Donahue, partner and antitrust attorney in the Chicago office of K&L Gates. “It’s across all industries, but health care has been a focus of the Biden administration for enforcement actions.”
Read more:Congress Members Look To Strengthen Federal Privacy Laws In Medical Data
After a 30-day preliminary assessment, the vast majority of deals examined by the FTC and Department of Justice are authorized. But according to Ms. Donahue, a court injunction can be invoked to prevent two organizations from coming together for antitrust purposes, reported Post Gazette.
A non-binding letter of intent to pursue an affiliation with UPMC, a $26 billion healthcare and insurance behemoth with 95,000 employees, was signed by the board of directors of Washington Health System in June. The deal’s financial specifics were kept confidential.
The two federal agencies share enforcement duties and the draft guidelines are just that — non-legally binding principles used to analyze deals that “reflect some key themes the agencies have highlighted in recent cases and advocacy, including concerns about concentration of markets, serial acquisitions, competition in labor markets and practices by dominant firms that cement their position and harm competition,” according to an advisory from the law firm of Buchanan Ingersoll & Rooney PC.
Source: Post Gazette
Featured News
EU Set to Review Rival Netflix and Paramount Skydance Bids for Warner Bros. Discovery
Jan 21, 2026 by
CPI
Judge Tosses Drug Pricing Conspiracy Case Against CVS, UnitedHealth, Evernorth
Jan 21, 2026 by
CPI
House Panel Alleges CVS Used Contracts to Suppress Pharmacy Competition
Jan 21, 2026 by
CPI
AI Is Changing M&A as Regulators Target ‘Killer Acquisitions’ and Data Control
Jan 21, 2026 by
CPI
Epic Games Brings in Veteran Tech Lawyer as Legal Chief
Jan 21, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Recidivism
Jan 21, 2026 by
CPI
Recidivism, Multiple Offending, and Serial Offending in Antitrust
Jan 21, 2026 by
Gregory Werden
Antitrust Recidivism: Why Repeat Cases Appear, and Why True Reoffending Is Rare in the United States
Jan 21, 2026 by
Lisa M. Phelan, Megan S. Golden, Adrienne Irmer & Nina Worth
99 Antitrust Problems – Is Recidivism One?
Jan 21, 2026 by
Brian A. Ratner & Kartik S. Madiraju
Holding A Cat by the Tail: A View of Cartel Recidivism in U.S. Antitrust Enforcement
Jan 21, 2026 by
Mark & KaDee L. Ru